Notch activation during early mesoderm induction modulates emergence of the T/NK cell lineage from human iPSCs.


Journal

Stem cell reports
ISSN: 2213-6711
Titre abrégé: Stem Cell Reports
Pays: United States
ID NLM: 101611300

Informations de publication

Date de publication:
13 12 2022
Historique:
received: 16 11 2021
revised: 06 10 2022
accepted: 07 10 2022
pubmed: 5 11 2022
medline: 17 12 2022
entrez: 4 11 2022
Statut: ppublish

Résumé

A robust method of producing mature T cells from iPSCs is needed to realize their therapeutic potential. NOTCH1 is known to be required for the production of hematopoietic progenitor cells with T cell potential in vivo. Here we identify a critical window during mesodermal differentiation when Notch activation robustly improves access to definitive hematopoietic progenitors with T/NK cell lineage potential. Low-density progenitors on either OP9-hDLL4 feeder cells or hDLL4-coated plates favored T cell maturation into TCRab

Identifiants

pubmed: 36332629
pii: S2213-6711(22)00503-3
doi: 10.1016/j.stemcr.2022.10.007
pmc: PMC9768581
pii:
doi:

Substances chimiques

Receptors, Notch 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2610-2628

Subventions

Organisme : NHLBI NIH HHS
ID : F32 HL149605
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020C00005
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interests Boston Medical Center has filed a patent application on the findings of this manuscript. G. Mostoslavsky is a scientific founder of and holds equity in Clade Therapeutics.

Références

J Exp Med. 2017 Nov 6;214(11):3347-3360
pubmed: 28931624
J Clin Invest. 1990 Mar;85(3):904-15
pubmed: 2312733
Nat Commun. 2021 Jan 18;12(1):430
pubmed: 33462228
Cell Stem Cell. 2018 Aug 02;23(2):252-265.e8
pubmed: 30082068
Blood. 2009 Feb 19;113(8):1689-98
pubmed: 19001083
J Exp Med. 2005 May 2;201(9):1361-6
pubmed: 15851488
Blood. 2012 Jun 14;119(24):5706-14
pubmed: 22431573
Cell Stem Cell. 2013 Nov 7;13(5):535-48
pubmed: 24054998
Trends Immunol. 2003 Apr;24(4):155-8
pubmed: 12697438
Methods. 2016 May 15;101:65-72
pubmed: 26439174
Dev Dyn. 2015 Mar;244(3):391-409
pubmed: 25641373
Immunity. 2017 Jul 18;47(1):183-198.e6
pubmed: 28723550
Nat Biotechnol. 2013 Oct;31(10):928-33
pubmed: 23934177
Cell Stem Cell. 2014 Sep 4;15(3):350-364
pubmed: 25130491
Blood. 1992 Feb 1;79(3):666-77
pubmed: 1370641
Nature. 2019 Oct;574(7778):365-371
pubmed: 31597962
Dev Cell. 2017 Mar 13;40(5):505-511.e6
pubmed: 28292428
J Immunol. 2014 May 1;192(9):4017-23
pubmed: 24748636
Cell Stem Cell. 2018 Dec 6;23(6):850-858.e4
pubmed: 30449714
Mech Dev. 2009 May-Jun;126(5-6):314-23
pubmed: 19275935
Eur J Cell Biol. 2018 Sep;97(7):512-522
pubmed: 30249464
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Mol Cell Biol. 2004 Oct;24(20):8813-22
pubmed: 15456857
Nat Immunol. 2004 Apr;5(4):410-7
pubmed: 15034575
Blood. 2005 Dec 1;106(12):3988-94
pubmed: 16091451
Nature. 2021 Dec;600(7888):285-289
pubmed: 34789876
Immunity. 2019 Nov 19;51(5):930-948.e6
pubmed: 31604687
Cell. 2015 Dec 17;163(7):1663-77
pubmed: 26627738
Int Immunol. 1999 Aug;11(8):1195-202
pubmed: 10421777
Blood. 2004 Nov 15;104(10):3097-105
pubmed: 15251982
Blood. 2007 May 15;109(10):4478-86
pubmed: 17272511
Nat Cell Biol. 2015 May;17(5):580-91
pubmed: 25915127
Cell Stem Cell. 2019 Mar 7;24(3):376-389.e8
pubmed: 30661959
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Stem Cells. 2018 Jul;36(7):1004-1019
pubmed: 29569827
Nat Rev Mol Cell Biol. 2016 Nov;17(11):722-735
pubmed: 27507209
BMC Immunol. 2011 Mar 23;12:22
pubmed: 21429219
Nature. 2011 Jun 08;474(7350):220-4
pubmed: 21654806
Dev Cell. 2015 Jun 22;33(6):729-36
pubmed: 26051539
Blood. 2006 Jul 1;108(1):116-22
pubmed: 16339407
Immunity. 2003 May;18(5):699-711
pubmed: 12753746
Nat Commun. 2018 May 8;9(1):1828
pubmed: 29739946

Auteurs

Dar Heinze (D)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA; Department of Surgery, Boston University Medical Center, Boston, MA, USA.

Seonmi Park (S)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Andrew McCracken (A)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Mona Haratianfar (M)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Jonathan Lindstrom (J)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Carlos Villacorta-Martin (C)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Aditya Mithal (A)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Feiya Wang (F)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Meng Wei Yang (MW)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

George Murphy (G)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.

Gustavo Mostoslavsky (G)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA; Department of Medicine, Section of Gastroenterology at Boston University and Boston Medical Center, Boston, MA, USA. Electronic address: gmostosl@bu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH